Pfizer Inc. $PFE Shares Bought by Jones Financial Companies Lllp

Jones Financial Companies Lllp lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.6% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 4,638,683 shares of the biopharmaceutical company’s stock after acquiring an additional 117,340 shares during the quarter. Jones Financial Companies Lllp’s holdings in Pfizer were worth $112,666,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Godfrey Financial Associates Inc. purchased a new stake in Pfizer in the fourth quarter valued at $26,000. Keb Asset Management LLC purchased a new position in shares of Pfizer during the second quarter worth about $26,000. HFM Investment Advisors LLC increased its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares in the last quarter. Finally, Abound Financial LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at about $31,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Pfizer stock opened at $28.53 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The business has a 50 day simple moving average of $25.39 and a 200-day simple moving average of $26.27. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The stock has a market capitalization of $162.60 billion, a PE ratio of 37.54 and a beta of 0.34.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.0%. Pfizer’s payout ratio is presently 226.32%.

Analyst Ratings Changes

A number of research firms recently issued reports on PFE. Wolfe Research restated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. BMO Capital Markets lowered their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Citigroup upped their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.28.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.